Dr. Reddy’s shares in focus after $50.5 million acquisition marking anti-vertigo foray

The acquisition strengthens Dr. Reddy’s Central Nervous System (CNS) Portfolio in India and Emerging Markets through its foray into the antivertigo segment.

Leave a Reply

Your email address will not be published. Required fields are marked *